Dr Robyn Sayer (MD FACOG FRANZCOG CGO) is a sub-specialty fellowship-trained gynaecologic cancer surgeon.
While Australian born, Dr Sayer underwent all of her higher education, medical training and early consultant work in the United States. Dr Sayer received her university degree in biology from Boston University in 1993. Following university, Dr Sayer spent several years pursuing basic science research interests at the University of Pennsylvania before attended medical school at Drexel University School of Medicine in Philadelphia. Her general obstetrics and gynaecology training was completed at Duke University in North Carolina in 2003 followed by 3 years of subspecialty gynaecologic oncology fellowship training at the University of South Florida / H. Lee Moffitt Cancer Center in Tampa, Florida. Dr Sayer received several awards for research in ovarian cancer during her training including the Berlex Foundation Faculty Development award, 10th Annual Helen Harris Memorial Trust, and the ASCO Foundation Merit Award. Following training, Dr Sayer stayed on as an assistant professor at the University of South Florida before joining a private practice gynaecologic oncology group in nearby Clearwater, Florida. She returned home to Australia in 2010 taking up a staff specialist appointment in the Gynaecologic Cancer Centre at the Royal Hospital for Women and The Canberra Hospital. Dr Sayer currently consults privately both in Sydney and Canberra.
Dr Sayer’s interest and expertise are in the surgical management and aftercare of women with gynaecologic malignancies (ovarian, peritoneal, uterine, cervical, vaginal and vulvar cancers). Dr Sayer’s surgical expertise encompasses radical pelvic surgery including radical tumour resections, bowel surgery, urologic surgery and cancer-associated reconstructive procedures. She has extensive experience in minimally invasive surgical techniques including laparoscopic and robotic-assisted surgery. Dr Sayer also has an interest in complex benign gynaecologic surgery including patients with extensive abdominal surgical histories and obesity. Dr Sayer also performs minimally invasive risk-reducing surgeries for patients at an increased risk of ovarian, tubal and/or uterine cancers due to a hereditary disposition (BRCA, Lynch Syndrome, etc).
Senior Staff Specialist, Chris O’Brien Lifehouse
Visiting Medical Officer, Prince of Wales Private Hospital
Visiting Medical Officer, Macquarie University Hospital
Visiting Medical Officer, Calvary John James Hospital (Canberra)
Visiting Medical Officer, National Capital Private Hospital (Canberra)
- Havrilesky, LJ, Alvarez, AA, Sayer, RA, Lancaster, JM, Soper, JT, Berchuck, A, Clarke-Pearson, DL, Rodriguez, GC, Carney, ME. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 2003;88:51-57.
- Sayer, R, Amundsen, C. Massive retroperitoneal leiomyoma arising from the rectal wall. Obstet Gynecol 2003;101:1132-1134.
- Lancaster, JM, Sayer, R, Blanchette, C, Calingaert, B, Whitaker, R, Schildkraut, J, Marks, J, Berchuck, A. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Canc Res 2003;9:762-766.
- Sayer, RA, Lancaster, JM, Pittman, J, Gray, J, Whitaker, R, Marks, JR, Berchuck, A. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 2005;96:355-361.
- Alvarez Secord, A, Sayer, R, Snyder, SA, Broadwater, G, Rodriguez, GC, Berchuck, A, Blackwell, K. The relationship between serum vascular endothelial growth factor (VEGF), persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol Oncol. 2004;94:74-79.
- Lancaster, JM, Sayer, RA, Blanchette, C, Calingaert, B, Konidari, I, Gray, J, Schildkraut, J, Schomberg, DW, Marks, JR, Berchuck, A. High expression of insulin-like growth factor binding protein-2 (IGFBP-2) messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006;16:1529-35.
- Lancaster, JM, Dressman, HK, Clarke JP, Sayer, RA, Martino, MA, Cragun, JM, Henriott, AH, Gray, J, Sutphen, R, Elahi, A, Whitaker, RS, West, M, Marks, JR, Nevins, JR, Berchuck, A. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer. 2006;16:1733-45.
- Dressman, HK, Berchuck, A, Chan, G, Zhai, J, Bild, A, Sayer, R, Cragun, J, Clarke, J, Whitaker, RS, Li, L, Gray, J, Marks, J, Ginsburg, GS, Potti, A, West, M, Nevins, JR, Lancaster, JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007;25:517-525.
- Sayer, RA, Deutsch, A, Hoffman, MS. Clitoroplasty. Obstet Gynecol. 2007;110:523-525.
- Tebes, SJ, Sayer, RA, Palmer, JM, Tebes, CC, Martino, MA, Hoffman, MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007;106:482-7.
- Hoffman, MS, Tebes, SJ, Sayer, RA, Lockhart, J. Extended cytoreduction of intraabdominal metastatic ovarian cancer in the left upper quadrant utilizing en bloc resection. Am J Obstet Gynecol. 2007;197:209.
- Deutsch, A, McCarthy, J, Sayer, R. Why are fewer medical students in Florida choosing obstetrics and gynecology? South Med J. 2007;100:1095-8.
- Hoffman, MS, Williams, V, Salihu, HM, Gunasekaran, S, Sayer, RA, Hakam, A, Roberts, WS. The vascular portion of the cardinal ligament: surgical significance during radical hysterectomy for cervical cancer. Am J Obstet Gynecol. 2008;199:191-3.